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Experience in Imaging Medullary Thyroid Carcinoma Using ^^""Tc (V)
Dimercaptosuccinic Acid (DMSA)
Susan Clarke,* Colin Lazarus,* and Michael Maisey*

wmj^ (V) dimercaptosuccinic acid (DMSA) is a new tumor imaging agenl that has been successfully
used to image patients with medullary thyroid carcinoma (MTC). Since 1986, studies have been
performed in 32 patients wilh histologically proven MTC al Guy's Hospital, London, England. Five
patients with primary tumor were studied prior lo surgery, four patients were studied after successful
removal oflhe primary tumor, and 26 patients with biochemical evidence of recurrence were studied.
Eight patients were studied serially to assess progression of disease, and four patients were studied
before and afler surgery. Twenty-one of the 26 patients with disease had positive scans with four falsenegative scans and three true negative scans. One patient had a false-positive scan (sensitivity 80%,
specificity 75%). Two of the false-negative scans were obtained in patients wilh moderate but stable
elevations of calcitonin hut no olher evidence of recurrence. One false-negative scan was obtained in a
patient who was discovered on screening to have an abnormal pentagastrin response, and a small 1 cm
tumor was subsequently removed. Uptake in local neck recurrence was frequently interne, but uptake
at sites of bone metastases was less marked. '^'"Tc (V) DMSA is an inexpensive radiopharmaceutical
which produces good quality images and has been shown to have an acceptable sensitivity and
specificity in the follow-up of patients with MTC and ihereby contributes significantly to the
management of these patients. (Henry Ford Hosp MedJ 1989;37:167-8)

n 1984 Ohta et al (I) reported their experience of imaging patients with known malignancy using a newly developed technetium 99m-labeled radiopharmaceutical, pentavatent dimercaptosuccinic acid ([V] DMSA). Of the parients imaged, five
had medullary thyroid carcinoma (MTC) and alt showed uptake
of'"^Tc (V) DMSA in their tumors. Other groups have atso reported success in imaging patients with MTC. In 1988 Patel et al
(2) reported 15 MTC patients and showed positive localization in
80% of those studied. In 1989 Guerra etal (3) studied 26 patients
with MTC using '^'"Tc (V) DMSA and showed a sensitivity of
84.2% for the technique. Following the 1987 report of our experience using ''^"'Tc (V) DMSA to image ten parients with MTC
when a sensitivity of 80% was achieved (4), we now report our
four-year experience of using '^"'Tc (V) DMSA in routine management of patients with histologically proven MTC.

I

Patients and Methods
The 32 parients studied included ten mates and 22 females
ranging in age from 14 to 86 years. Of these patients, 26 had
sporadic MTC, four had multiple endocrine neoplasia type 2A
(MEN 2A), and two had MEN 2B. Five patients with primary
tumors were studied prior to surgery, four patients were studied
after successful removal of the primary tumor, and 26 patients
with biochemical evidence of residual or recunent tumor were
studied. Eight patients were studied serially to assess the progression of disease, and four were studied before and after surgery. A total of 56 scans were performed. Alt patients were evaluated by '""'Tc medronate methylene diphosphonate (MDP)
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bone scans, chest roentgenograms, and computed tomography
to define accurately the extent of their disease.
•"•"Tc (V) DMSA was prepared using the previousty reported
method (4) and labeled with 370 MBq (10 mCi) of '"-"Tc. Following intravenous administration, whole body images were acquired at 3 hours using a large field of view gamma camera and a
general all-purpose collimator. No image enhancement was
used, although singte photon emission computed tomography
(SPECT) was perfonned in two patients to define accurately the
extent of their neck recunence before surgery.

Results
Uptake of''"Tc (V) DMSA varied from intense to slight. Uptake in small lesions less than 1 cm and in bone metastases was
usually less than the uptake in softfissuedisease. Of the five
patients with primary tumors, one patient showed no significant
uptake in the thyroid. This 17-year-old girl, the sibling of a
known case of MEN 2A, had an abnormal calcitonin (CT) response to pentagastrin. At surgery a smalt focus of MTC, about
1 cm in diameter, was discovered. The other four patients with
primary tumors showed positive uptake on imaging, and in two
patients involved local lymph nodes were atso imaged.
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In the patients studied postoperatively, the four patients with
successful removal of tumors had negative scans. In two other
patients studied postoperatively, involvement of mediastinal
nodes necessitated sternal splitting to approach the mediastinum. Postoperative scans showed uptake in both patients in
unresectable tumor and atso in the stemum at tbe site of surgery.
Two pafients were studied following radiotherapy to the neck,
and both showed tow grade diffuse uptake in the neck within the
radiotherapy field.
Ofthe 26 patients studied with biochemical evidence of recurrence, four patients had false-negative studies with no abnormal
uptake of ''"Tc (V) DMSA visualized. Three of the four patients
had stable CT levels, and no disease could be imaged despite
extensive investigarion with computed tomography and ""Tc
MDP bone imaging. In one pafient with diffuse lung metastases,
uptake was initially negative but subsequently became positive
as the metastases increased in size. The remaining 22 patients
had uptake on imaging. The degree of ""Tc (V) DMSA accumulation varied with site of uptake, and uptake in sites of neck
recurrence was frequently intense whereas uptake in bone metastases was tess marked and frequently identified only when the
""Tc (V) DMSA study was reviewed with a ""Tc diphosphonate bone scan.

Discussion
No successful treatment cunently exists for the management
of some MTC patients. Surgery of the primary tumor, if performed early before local lymph nodes become invotved, may
be followed by a tong disease-free interval. Primary surgery
when local lymph nodes are invotved, however, remains only
palliative despite attempts at extensive neck and mediastinal resections. The slow-growing nature of tumor has encouraged
many surgeons to attempt extensive dissections to debulk the tumor, reduce symptoms caused by vasoactive peptides, and give
the patient several years of relative symptom-free existence.
Other therapeutic options tried in recent years but with little success inctude extemal beam radiotherapy, chemotherapy, and " ' I
meta-iodo-benzylguanidine therapy (5,6). One of the main
problems in the assessment of new therapies for this disease is
the inability to define accurately the extent and activity of the
disease and therefore to assess its response to therapy. Radionuclide techniques such as ""Tc diphosphonate bone scanning,
""Tc colloid, and ""Tc pertechnetate gtucoheptonate have been
shown to be sensifive techniques for idenfifying metastatic disease in the bone, liver, and brain, respectivety, but do not accurately define the extent of the primary disease or local recurrence, -"'thallous chloride has been used to image MTC (7,8),
but although uptake in the primary tumor or tocal recunence is
marked, the normal biodistribution of ''^'thallous chloride in the
myocardium, lungs, and liver significantly diminishes the
usefulness of this agent to image metastases in these sites.
Both ultrasound and computed tomography may be used to
assess the neck for recunence, but their specificity is low when

168 Henry Ford Hosp Med J—Vol 37. Nos 3 & 4, 1989

assessing the involvement of lymph nodes, which are frequently
enlarged secondary to inflammatory change rather than metastatic involvement. Surgery with major neck and mediastinal
dissection atso produces gross distortion of the normal anatomy
and may make interpretation of both computed tomography and
ultrasound images difficult. Therefore, there is a need for an
imaging technique that witt accurately define the extent and activity of primary and metastatic disease so that as new
therapeutic agents are developed their efficacy may be readity
assessed. ""Tc (V) DMSA is inexpensive and can be easily prepared in most nuclear medicine departments. Because there is
littie nonspecific uptake of the agent, it produces excellent images which require no processing. It is also an ideal agent for
SPECT studies, although SPECT is usually unnecessary because of the high uptake visualized on most planar studies.
False-positive images do occur following radiotherapy and
surgery involving bones, but awareness of this usually resolves
the problem when interpreting a posttherapy image. False-negative images occur when tumor volume is small, which in our
opinion is atso the cause of false-negative studies in the well recognized group of patients whose CT levels fait to fall to the normal range in the postoperative period and remain elevated but do
not increase. This phenomenon may partly explain the negative
results reported by Hitditch et at (9).
""Tc (V) DMSA has been demonstrated in an increasing
number of patients to be the imaging method of choice in the
follow-up of patients with MTC to define accurately the presence and extent of disease.
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